Skip to main content
Erschienen in: Journal für Klinische Endokrinologie und Stoffwechsel 2/2020

13.12.2019 | Onkologie und Hämatologie | Originalien

Transplantation bei Lebermetastasen neuroendokriner Tumoren – Heilung oder Palliation?

verfasst von: PD Dr. Daniela Kniepeiss, MBA, Univ.-Prof. Prof. (hon.) Dr. med. Dr. h.c. Peter Schemmer, MBA, FACS

Erschienen in: Journal für Endokrinologie, Diabetologie und Stoffwechsel | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die insgesamt seltenen neuroendokrinen Tumoren (NET) sind bezüglich Lokalisation, Dignität und Prognose heterogen. Oft besteht zum Zeitpunkt der Diagnosestellung bereits eine Lebermetastasierung. Kurative Behandlungsmethoden sind bei negativer Umfelddiagnostik die Leberresektion oder Lebertransplantation. Die Selektionskriterien für eine chirurgische Therapie werden allerdings nur von einem kleinen Teil der Patienten erfüllt. Zur Palliation stehen zusätzlich interventionell radiologische, medikamentöse und nuklearmedizinische Therapien zur Verfügung.
Während im kurativen Setting aufgrund der geringen Fallzahlen randomisierte, kontrollierte Studien (RCT) fehlen, wurden bisher bei palliativen Patienten lediglich Systemtherapien miteinander verglichen. Die meisten Daten stammen aus retrospektiven Studien mit durch die Heterogenität der Erkrankung und durch die Variabilität der beschriebenen Selektionskriterien limitierter Aussagekraft.
Patienten mit metastasiertem NET müssen in hochspezialisierten Zentren interdisziplinär diskutiert und, wenn ein kurativer Ansatz nicht möglich ist, in einem palliativen Setting multimodal therapiert werden.
Literatur
1.
Zurück zum Zitat Duggan MA, Anderson WF, Altekruse S et al (2016) The surveillance, epidemiology and end results (SEER) program and pathology: towards strengthening the critical relationship. Am J Surg Pathol 40(12):94–102CrossRef Duggan MA, Anderson WF, Altekruse S et al (2016) The surveillance, epidemiology and end results (SEER) program and pathology: towards strengthening the critical relationship. Am J Surg Pathol 40(12):94–102CrossRef
2.
Zurück zum Zitat Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265CrossRef Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265CrossRef
3.
Zurück zum Zitat Davies L, Weickert MO (2016) Gastroenteropancreatic neuroendocrine tumours: an overview. Br J Nurs 25(4):12–15CrossRef Davies L, Weickert MO (2016) Gastroenteropancreatic neuroendocrine tumours: an overview. Br J Nurs 25(4):12–15CrossRef
4.
Zurück zum Zitat Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the digestive system. IARC, Lyon, S 13–14 Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the digestive system. IARC, Lyon, S 13–14
5.
Zurück zum Zitat Öberg K, Knigge U, Kwekkeboom D et al (2012) ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):124–130CrossRef Öberg K, Knigge U, Kwekkeboom D et al (2012) ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):124–130CrossRef
6.
Zurück zum Zitat Cai W, Tan Y, Ge W et al (2018) Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 7(6):2699–2709CrossRef Cai W, Tan Y, Ge W et al (2018) Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 7(6):2699–2709CrossRef
7.
Zurück zum Zitat Steinmüller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62CrossRef Steinmüller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62CrossRef
8.
Zurück zum Zitat Yao JC, Hassan M, Phan A et al (2008) One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef Yao JC, Hassan M, Phan A et al (2008) One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef
9.
Zurück zum Zitat Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176CrossRef Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176CrossRef
10.
Zurück zum Zitat Sarmiento JM, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRef Sarmiento JM, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRef
11.
Zurück zum Zitat Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133:375–382CrossRef Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133:375–382CrossRef
12.
Zurück zum Zitat Chamberlain R, Canes D, Brown K et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432–445CrossRef Chamberlain R, Canes D, Brown K et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432–445CrossRef
13.
Zurück zum Zitat Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783CrossRef Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783CrossRef
14.
Zurück zum Zitat Kianmanesh R, O’Toole D, Sauvanet A et al (2005) Surgical treatment of gastric, enteric, and pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris) 142:208–219CrossRef Kianmanesh R, O’Toole D, Sauvanet A et al (2005) Surgical treatment of gastric, enteric, and pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris) 142:208–219CrossRef
15.
Zurück zum Zitat Mazzaferro V, Pulvirenti A, Coppa J (2007) Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 47(4):460–466CrossRef Mazzaferro V, Pulvirenti A, Coppa J (2007) Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 47(4):460–466CrossRef
16.
Zurück zum Zitat Oetal N, Stalberg P, Zedenius J et al (2013) Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 100:1505–1514CrossRef Oetal N, Stalberg P, Zedenius J et al (2013) Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 100:1505–1514CrossRef
17.
Zurück zum Zitat Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13:572–581CrossRef Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13:572–581CrossRef
18.
Zurück zum Zitat Du S, Ni J, Weng L et al (2015) Aggressive locoregional treatment improves the outcome of liver metastases from grade 3 gastroenteropancreatic neuroendocrine tumors. Medicine (Baltimore) 94:e1429CrossRef Du S, Ni J, Weng L et al (2015) Aggressive locoregional treatment improves the outcome of liver metastases from grade 3 gastroenteropancreatic neuroendocrine tumors. Medicine (Baltimore) 94:e1429CrossRef
19.
Zurück zum Zitat Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 66:1307–1312CrossRef Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 66:1307–1312CrossRef
20.
Zurück zum Zitat Florman S, Toure B, Kim L et al (2004) Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 8:208–212CrossRef Florman S, Toure B, Kim L et al (2004) Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 8:208–212CrossRef
21.
Zurück zum Zitat Frilling A, Malago M, Weber F et al (2006) Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl 12:1089–1096CrossRef Frilling A, Malago M, Weber F et al (2006) Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl 12:1089–1096CrossRef
22.
Zurück zum Zitat Le Treut YP, Gregoire E, Belghiti J et al (2008) Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 8:1205–1213CrossRef Le Treut YP, Gregoire E, Belghiti J et al (2008) Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 8:1205–1213CrossRef
23.
Zurück zum Zitat Van Vilsteren F, Baskin-Bey E, Nagorney D et al (2006) Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 12:448–456CrossRef Van Vilsteren F, Baskin-Bey E, Nagorney D et al (2006) Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 12:448–456CrossRef
24.
Zurück zum Zitat Mazzaferro V, Sposito C, Coppa J et al (2016) The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 16:2892–2902CrossRef Mazzaferro V, Sposito C, Coppa J et al (2016) The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 16:2892–2902CrossRef
25.
Zurück zum Zitat Sposito C, Busset M, Citterio D et al (2017) The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons. Rev Endocr Metab Disord 18:473–483CrossRef Sposito C, Busset M, Citterio D et al (2017) The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons. Rev Endocr Metab Disord 18:473–483CrossRef
26.
Zurück zum Zitat Mohan H, Nickolson P, Winter DC et al (2015) Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 26:935–942CrossRef Mohan H, Nickolson P, Winter DC et al (2015) Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 26:935–942CrossRef
27.
Zurück zum Zitat Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47:177–182CrossRef Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47:177–182CrossRef
28.
Zurück zum Zitat Rinke A, Wittenberg M, Schade-Brittinger C et al (2017) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology 104:26–32CrossRef Rinke A, Wittenberg M, Schade-Brittinger C et al (2017) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology 104:26–32CrossRef
29.
Zurück zum Zitat Caplin ME, Pavel M, Cwikla JB et al (2016) Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23:191–199CrossRef Caplin ME, Pavel M, Cwikla JB et al (2016) Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23:191–199CrossRef
30.
Zurück zum Zitat Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135CrossRef Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135CrossRef
31.
Zurück zum Zitat Rosenau J, Bahr M, Von Wasielewski R et al (2002) Ki67, E‑cadherin and p53 as prognostic indicators of long term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73:386–394CrossRef Rosenau J, Bahr M, Von Wasielewski R et al (2002) Ki67, E‑cadherin and p53 as prognostic indicators of long term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73:386–394CrossRef
32.
Zurück zum Zitat La Salvia A, Partelli S, Tampellini M et al (2016) Management of hepatic metastases of well/moderately differentiated neuroendocrine tumors of the digestive tract. J Cancer Metastasis Treat 2:294–303CrossRef La Salvia A, Partelli S, Tampellini M et al (2016) Management of hepatic metastases of well/moderately differentiated neuroendocrine tumors of the digestive tract. J Cancer Metastasis Treat 2:294–303CrossRef
33.
Zurück zum Zitat Rinke A, Wiedenmann B, Auernhammer C et al (2018) S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 56:583–681CrossRef Rinke A, Wiedenmann B, Auernhammer C et al (2018) S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 56:583–681CrossRef
Metadaten
Titel
Transplantation bei Lebermetastasen neuroendokriner Tumoren – Heilung oder Palliation?
verfasst von
PD Dr. Daniela Kniepeiss, MBA
Univ.-Prof. Prof. (hon.) Dr. med. Dr. h.c. Peter Schemmer, MBA, FACS
Publikationsdatum
13.12.2019
Verlag
Springer Vienna
Erschienen in
Journal für Endokrinologie, Diabetologie und Stoffwechsel / Ausgabe 2/2020
Print ISSN: 3004-8915
Elektronische ISSN: 3004-8923
DOI
https://doi.org/10.1007/s41969-019-00087-4

Weitere Artikel der Ausgabe 2/2020

Journal für Klinische Endokrinologie und Stoffwechsel 2/2020 Zur Ausgabe

Genetisches Alphabet

GNAS-assoziierte Erkrankungen

Editorial

Editorial